Formulation dependent pharmacokinetics, bioavailability and renal toxicity of a selective cyclooxygenase-1 inhibitor sc-560 in the rat

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 6, Issue 2, 2003, Pages 205-210

  Teng, Xiao Wei ^a   Abu Mellal, Abdallalah ^b   Davies, Neal M ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; CHLORIDE; CYCLOOXYGENASE 1 INHIBITOR; ELECTROLYTE; MACROGOL; METHYLCELLULOSE; N ACETYL BETA GLUCOSAMINIDASE; POTASSIUM; SODIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CHLORIDE URINE LEVEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TISSUE LEVEL; ELECTROLYTE URINE LEVEL; ENZYMURIA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; JUGULAR VEIN; LIVER BLOOD FLOW; MALE; NEPHROTOXICITY; NONHUMAN; POTASSIUM URINE LEVEL; RAT; SODIUM URINE LEVEL; URINALYSIS; URINARY EXCRETION; VENOUS BLOOD;

ABSORPTION; ACETYLGLUCOSAMINIDASE; ADMINISTRATION, ORAL; ANIMALS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; CYCLOOXYGENASE 1; CYCLOOXYGENASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; ISOENZYMES; MALE; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0141541775     PISSN: 14821826     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Smith, C. J., Zhang, Y., Koboldt, C. M., Muhammad, J., Zweifel, B. S., Shaffer, A., Talley, J. J., Masferrer, J. L., Seibert, K., Isakson, P, C., Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc Natl Acad Sci U S A, 95:13313-13318, 1998.
2. Masferrer, J.L., Zweifel, B.S., Manning, P.T., Selective inhibition of inducible cyclooxygenase2 in vivo is antiinflammatory and nonulcerogenic. Proc Natl Acad Sci U S A, 91: 3228-3232, 1994.
3. Wallace, J.L., McKnight, W., Reuter, B.K, Vergnolle, N., NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology 119: 706-714, 2000.
4. Sawdy, R.J., Slater, D.M., Dennes, W.J., Sullivan, M.H., Bennett, P.R., The roles of the cyclo-oxygenases types one and two in prostaglandin synthesis in human fetal membranes at term. Placenta 21: 54-57, 2000.
5. Gretzer, B., Maricic, N., Respondek, M., Schuligoi, R., Peskar, B.M., Effects of specific inhibition of cyclo-oxygenase-1 and cyclo-oxygenase-2 in the rat stomach with normal mucosa and after acid challenge. Br J Pharmacol 132: 1565-1573, 2000.
6. Loftin, C.D., Trivedi, D.B., Langenbach. R., Cyclooxygenase-1-selective inhibition prolongs gestation in mice without adverse effects on the ductus arteriosus. J Clin Invest 110: 549-557, 2002.
7. Tanaka, A., Hase, S., Miyazawa, T., Takeuchi, K., Up-regulation of cyclooxygenase-2 by inhibition of cyclooxygenase-1: a key to non-steroidal anti-inflammatory drug-induced intestinal damage. J Pharmacol Exp Ther 300: 754-761, 2002.
8. Davies, N.M., McLachlan, A.J., Day, R.O., Williams, K.M., Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet 38: 225-242, 2000.
9. Teng, X.W., Davies, N.M., High-Performance Liquid Chromatographic Analysis of a Selective Cyclooxygenase-1 Inhibitor SC-560 in Rat Serum. J Pharm Biomed Anal In press 2003.
10. Shah, V.P., Midha, K.K., Dighe, S., McGilveray, I.J., Skelly, J.P., Yacobi, A., Layloff, T., Viswanathan, C.T., Cook, C.E., McDowall, R.D., Pittman, K.A., Spector, S., Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. Conference report. Eur J Drug Metab Pharmacokinet. 16: 249-255, 1991.
11. Guirguis, M.S., Sattari, S., Jamali, F., Pharmacokinetics of celecoxib in the presence and absence of interferon-induced acute inflammation in the rat: application of a novel HPLC assay. J Pharm Pharmaceut Sci 4: 1-6, 2001.
12. Davies, B., Morris, T. Physiological parameters in laboratory animals and humans. Pharm Res 10: 1093-1095, 1993.
13. Piquette-Miller, M., Jamali, F., Selective Effect of Adjuvant arthritis on the disposition of propranolol enantiomers in rats detected using a stereospecific HPLC assay. Pharm Res 10: 294-299, 1993.
14. Johnson, P.M., Vogt, S.K., Burney, M.W., Muglia, L.J., COX-2 inhibition attenuates anorexia during systemic inflammation without impairing cytokine production. Am J Physiol Endocrinol Metab 282: E650-E656, 2002.
15. Rudnick, D.A., Perlmutter, D.H., Muglia, L.J., Prostaglandins are required for CREB activation and cellular proliferation during liver regeneration. Proc Natl Acad Sci U S A 98: 8885-8890, 2001.
16. Lopez-Parra, M., Claria, J., Planaguma, A., Titos, E., Masferrer, J.L, Woerner, B.M, Koki, A.T., Jimenez, W., Altuna, R., Arroyo, V., Rivera, F., Rodes, J., Cyclooxygenase-1 derived prostaglandins are involved in the maintenance of renal function in rats with cirrhosis and ascites. Br J Pharmacol 135: 891-900, 2002.
17. Porter, G.A., Norton, T.L., Legg, V., Using urinary biomarkers to evaluate renal effects of a COX-2 NSAID in volunteers. Renal Failure 21: 311-317, 1999.
18. Meyer, B.H., The use of renal enzymes as early indication of renal toxicity after multiple-dose administration of aspirin. South Af Med J 63: 687-688, 1983.
19. Abu-Mellal, A.M., Investigations of renal and gastrointestinal toxicity of selected anti-inflammatory drugs in a rat model. MSc Thesis University of Sydney 2002.